Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Cipla Limited has a licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; a license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.

Metric
Company Name	Cipla Limited
Symbol	CIPLA
MSH ID	COM:CIPLA
Market	STOCKS
Sector	Healthcare
Industry	Drug Manufacturers - General
Country	IN
Stage
Employee Count	32.32K
Website	cipla.com
LinkedIn
Founders

Metric
Market Cap	14.36B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	3.04B
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.37B
EBITDA	742.73M
Operating Income	618.64M
Net Income	486.60M
EPS	0.60
Diluted EPS	0.60
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.65
Operating Profit Margin	0.22
EBITDA Margin	0.24
Net Profit Margin	0.17
Return on Equity	0.21
Return on Assets	0.13
Return on Capital Employed	0.21

COM:CIPLA

Cipla Limited

Last Close

1,486.50

25/11 09:40

Market Cap

1.22T

Beta: -

Volume Today

1.45M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	31.22
P/B Ratio	4.66
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.23
EV Multiple	18.58

Metric
Days Sales Outstanding	78.59
Days Payables Outstanding	110.55
Days Inventory Outstanding	187.58
Operating Cycle	255.80
Cash Conversion Cycle	167.20
Asset Turnover	0.79

Metric
Operating Cash Flow	504.98M
Free Cash Flow	345.68M
Cash Flow to Debt	2.80
Operating Cash Flow/Sales	0.06
Free Cash Flow Yield	0.00

Metric
Cash & Equivalents	103.30M
Accounts Receivable	-107.08M
Inventory	618.40M
Goodwill	367.41M
Debt to Capitalization	0.02
Debt to Assets	0.03
Current Ratio	3.37
Quick Ratio	2.70

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.00
R&D to Revenue
SG&A to Revenue